Table 3.

Clinical follow-up

Patient	Time to clinical follow-up (mo)	NIS at initial eval (points)	NIS at follow-up eval (points)	Dyck Score	QST	NCS/EMG	CMAP (mV) initial eval	CMAP (mV) follow-up	MRI
1	12	12.25	13.75	3	HS vibration	Slight progression	11.4	10.7	No change
2	10	12	11	3	HA heat pain	Slight progression	12.8	11.2	No change
3	20	30	32.75	4		No Change	0	0.0	No change
4	61	7	10	3					No change
6	57	20	21			No Change	0	0.0	No change
12	77	2	3.25	3					No change
14	41	19	20.25	4	HS vibration and heat pain	Slight progression	11	9.9	No change
15	247	21.5	49			Progression	8.2	0.0
16	48	6	1	2	HS vibration	Improvement	2.1	4.8	No change
18	24	22	24	4	HS vibration	No Change	6	6.4	No change
19	54	12	17	3		Improvement	13	16.6	No change
25	33	18				Slight progression	0.4	0.0
27	56	8				No Change	0	0.0
29	14	13	12.75	5	HS vibration, HA heat pain	No Change	9.8	9.4	No change
Number	15	15	12	10	6	12	12	12	11
Median	44.5	12.6*	15.4*	3			7.1*	5.6*
Range	10–247	2–30	1–49	2–5			0–13	0–16.6

NIS = neuropathy impairment score; QST = quantitative sensory testing; NCS/EMG = nerve conduction studies and electromyography; CMAP = compound muscle action potential; HS = hyposensitivity; HA = hyperalgesia.

*P-values for change over time not significant using paired t-tests.